AOD 9604 vs sermorelin comes down to mechanism: one targets fat cells directly, the other boosts growth hormone. Compare effects, dosing, and safety here.
AOD-9604 and sermorelin are different classes of peptide that are often compared for body composition, but they do not work the same way. AOD-9604 is a modified fragment of human growth hormone studied for direct effects on fat cells, while sermorelin is a growth hormone-releasing hormone (GHRH) analog that tells the pituitary gland to produce more growth hormone. Neither peptide is FDA-approved for weight loss or anti-aging use in the United States.
What Is AOD-9604?
AOD-9604 is a 15-amino-acid piece of human growth hormone, also known as HGH 176-191. It copies the region of HGH linked to fat breakdown while leaving out the parts associated with growth, blood sugar shifts, and IGF-1 production.
Because AOD-9604 does not raise growth hormone or IGF-1 levels, it is studied as a targeted fat-metabolizing compound rather than a general growth hormone booster.
- Early animal studies and one small human trial reported reductions in body fat.
- Larger clinical trials run by Metabolic Pharmaceuticals in the 2000s did not show meaningful weight loss compared with placebo.
- Research interest continues in obesity and metabolic health, often alongside other experimental compounds.
AOD-9604 is not FDA-approved for any human use, and it is sold almost exclusively as a research chemical labeled "not for human consumption."
What Is Sermorelin?
Sermorelin is a 29-amino-acid GHRH analog, which means it mimics the natural hormone your hypothalamus uses to signal growth hormone release. Instead of acting on fat cells directly, it works upstream at the pituitary.
The peptide was FDA-approved as Geref for evaluating and treating growth hormone deficiency in children, but that product was discontinued in the United States. Sermorelin is now most often obtained through compounding pharmacies and is a fixture in anti-aging and wellness clinics.
- Raises both growth hormone and IGF-1, which can influence body composition, recovery, and sleep quality.
- Frequently combined with a growth hormone-releasing peptide such as ipamorelin or GHRP-2.
- Available as a subcutaneous injection and, in some clinics, as an intranasal spray.
Sermorelin is not currently FDA-approved as a commercial product, and compounded versions are not reviewed by the FDA for safety, effectiveness, or quality.
AOD-9604 vs Sermorelin: Side-by-Side Comparison
| Feature | AOD-9604 | Sermorelin |
|---|---|---|
| Peptide class | HGH fragment (HGH 176-191) | GHRH analog |
| Main mechanism | Acts directly on fat cells to support lipolysis | Signals the pituitary to release growth hormone |
| Effect on GH and IGF-1 | Little to none | Raises both |
| Primary research focus | Fat loss and metabolic health | GH deficiency, body composition, sleep, recovery |
| FDA status | Never approved for human use | Formerly approved as Geref; brand discontinued, now compounded |
| Common research dose | 250–500 mcg daily | 100–300 mcg at night |
| Reported side effects | Injection site reactions; generally mild in trials | Injection site reactions, flushing, headache, possible cortisol changes |
| Typical stack partners | Other experimental metabolic compounds | Ipamorelin, GHRP-2, CJC-1295 |
How Each Peptide Is Dosed in Research
Dosing for both peptides is experimental. There is no FDA-approved label that defines a safe or effective human dose for AOD-9604, and sermorelin's original prescribing information applied only to the discontinued Geref product.
- AOD-9604: research protocols commonly list 250–500 mcg per day, usually injected subcutaneously and sometimes split into two doses.
- Sermorelin: research and clinical protocols typically list 100–300 mcg at night, timed to coincide with the body's natural overnight GH pulse.
Anyone considering either peptide should speak with a licensed healthcare professional rather than relying on forum dosing advice or vendor recommendations.
Which Peptide Fits Which Goal?
The right option depends on what you are actually trying to change.
- Fat loss without raising growth hormone: AOD-9604 is the compound studied for that specific purpose, though the human trial data are weak.
- More natural growth hormone output: Sermorelin is the relevant choice because it stimulates the pituitary rather than bypassing it.
- Visceral fat in a clinical setting: Tesamorelin is the FDA-approved GHRH analog for HIV-associated lipodystrophy, which is why aod 9604 vs tesamorelin comes up so often in the same conversations.
- Combined mechanisms: Some protocols pair AOD-9604 with a GHRH analog, but no clinical trial has tested that combination.
Safety, Legality, and Sourcing
Both peptides carry real risk when purchased outside a legitimate medical channel. AOD-9604 and compounded sermorelin are unapproved for human use, so there is no guarantee of purity, correct dosing, or sterility.
Reported side effects for sermorelin include injection site reactions, flushing, and headaches, and higher doses may affect cortisol or prolactin. AOD-9604 has generally been described as well tolerated in trials, but those trials were short and small.
If you are exploring sermorelin vs aod 9604 for any health goal, the safest path is a conversation with a physician who can review your labs, your history, and whether an approved treatment would serve you better.
Related Peptide Comparisons
Peptide research rarely stops with one pairing. People comparing aod 9604 vs retatrutide are usually weighing older fat-loss peptides against modern GLP-1 based drugs, while aod 9604 vs mots-c shows up in metabolic research discussions about how different compounds influence energy balance. If your interest is pituitary-driven growth hormone release, aod-9604 vs cjc-1295 ipamorelin is a more relevant read than AOD-9604 versus sermorelin alone.
Frequently Asked Questions
Is AOD-9604 or sermorelin better for fat loss?
Sermorelin raises growth hormone and IGF-1, which can indirectly support fat loss, while AOD-9604 is designed to act on fat cells directly without raising growth hormone. Human trial results for AOD-9604 have been modest, and neither peptide is FDA-approved for weight loss. A doctor can help you compare these options with approved treatments.
Can AOD-9604 and sermorelin be stacked together?
Some people stack them on the theory that AOD-9604 supports fat breakdown while sermorelin increases natural growth hormone release. No clinical trial has tested the combination, so its safety and effectiveness are unknown. Stacking unapproved peptides also raises the risk of dosing errors and contaminated product.
Is sermorelin FDA-approved?
Sermorelin was FDA-approved under the brand name Geref, but that product was discontinued in the United States and is no longer commercially available. Compounded sermorelin is not FDA-approved, and AOD-9604 has never been approved for human use. Both are sold mainly as research chemicals.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.